|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-29
|
|
pubmed:abstractText |
With the aim to address the issue whether high-dose therapy (HDT) is required after new drugs combinations to improve outcome of elderly newly diagnosed multiple myeloma (MM) patients, we compared the toxicity and the outcome of ThaDD plus maintenance to those of ThaDD plus HDT-autologous stem cell transplantation (ASCT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1600-0609
|
|
pubmed:author |
pubmed-author:AlesianiFrancescoF,
pubmed-author:BrunoriMarinoM,
pubmed-author:BurattiniMaurizioM,
pubmed-author:CatariniMassimoM,
pubmed-author:CenturioniRiccardoR,
pubmed-author:CorvattaLauraL,
pubmed-author:FalcioniSadiaS,
pubmed-author:FraticelliPaoloP,
pubmed-author:GalieniPieroP,
pubmed-author:GentiliSilviaS,
pubmed-author:LeoniPietroP,
pubmed-author:MontanariMauroM,
pubmed-author:OffidaniMassimoM,
pubmed-author:PolloniClaudiaC,
pubmed-author:RuggieriMirianaM,
pubmed-author:SamoriArduinoA,
pubmed-author:SaviniAgneseA,
pubmed-author:VisaniGiuseppeG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
474-83
|
|
pubmed:meshHeading |
pubmed-meshheading:20331733-Aged,
pubmed-meshheading:20331733-Aged, 80 and over,
pubmed-meshheading:20331733-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20331733-Combined Modality Therapy,
pubmed-meshheading:20331733-Dexamethasone,
pubmed-meshheading:20331733-Disease-Free Survival,
pubmed-meshheading:20331733-Doxorubicin,
pubmed-meshheading:20331733-Female,
pubmed-meshheading:20331733-Humans,
pubmed-meshheading:20331733-Male,
pubmed-meshheading:20331733-Melphalan,
pubmed-meshheading:20331733-Multiple Myeloma,
pubmed-meshheading:20331733-Polyethylene Glycols,
pubmed-meshheading:20331733-Prospective Studies,
pubmed-meshheading:20331733-Stem Cell Transplantation,
pubmed-meshheading:20331733-Survival Analysis,
pubmed-meshheading:20331733-Thalidomide,
pubmed-meshheading:20331733-Transplantation, Autologous,
pubmed-meshheading:20331733-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
|
|
pubmed:affiliation |
Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona. m.offidani@ospedaliriuniti.marche.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
